Epizyme, Inc. (EPZM)
EPZMPrice: $1.47
Fair Value: 🔒
🔒score
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma fo... more
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Robert Bazemore |
| IPO Date | 2013-05-31 | CAGR | 0.18% |
| Employees | 250 | Website | www.epizyme.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
EPZM chart loading...
Fundamentals
Technicals
| Enterprise Value | $412.12M | P/E Ratio | -0.7 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | -7.17 |
| P/CF Ratio | -0.65 | P/FCF Ratio | — |
| EPS | $-2.09 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 62.69% | Gross Margin | 0.72% |
| Operating Margin | -6.06% | Profit Margin | -6.71% |
| ROE | -3.06% | ROA | -0.87% |
| ROCE | -0.93% | Current Ratio | 4.56 |
| Quick Ratio | 4.49 | Cash Ratio | 2.18 |
| Debt/Equity | -11.56 | Interest Coverage | -9.39 |
| Altman Z Score | — | Piotroski Score | — |